{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-251966","form_type":"8-K","ticker":null,"cik":"0001780097","company_name":"Baudax Bio, Inc.","filed_at":"2023-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.394950+00:00","generated_at":"2026-06-10T03:33:27.312518+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Baudax Bio Corporate Controller resigns; appoints Interim CFO via Danforth","bullets":["Jillian Dilmore resigns as Corporate Controller, PFO, PAO, and Corporate Secretary effective Oct 9, 2023; she will provide continued consulting support.","Board appoints Natalie McAndrew as Interim CFO effective Oct 9, 2023; she will also serve as PFO and PAO through Danforth Advisors.","McAndrew, age 49, is a Director at Danforth Advisors, a life science advisory firm; no family relationships with executives."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-251966","json":"https://secwatch.observer/filing/0001193125-23-251966.json","markdown":"https://secwatch.observer/filing/0001193125-23-251966.md","text":"https://secwatch.observer/filing/0001193125-23-251966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523251966/0001193125-23-251966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523251966/d416304d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:33:27.312518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c660f6e69","claim":"Jillian Dilmore resigned as Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary at Baudax Bio, Inc..","evidence_excerpt":"On October 2, 2023, Jillian Dilmore, the Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Baudax Bio, Inc. (the “Company”) notified the Company of her decision to resign effective as of October 9, 2023 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523251966/0001193125-23-251966-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Corporate Controller, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"3cee52b8a9","claim":"Natalie McAndrew was appointed as Interim Chief Financial Officer at Baudax Bio, Inc..","evidence_excerpt":"On October 5, 2023, the board of directors of the Company appointed Natalie McAndrew as Interim Chief Financial Officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1780097/000119312523251966/0001193125-23-251966-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}